CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleLevered free cash flow is $21.85M, above the global median of $16.24M
- PositionReturn on assets is 15.4%, higher than 95% of its Biotechnology peers (median -20.1%)
- Interpretations7 currently firing — 7
Sign in to view price data.
Sign inWhat the company actually pays, and whether its own cash supports it.
Dividends view
Yield
0.12%
Annual Rate
INR 1.00Paid annual
Payout Ratio
4.1%Sustainable
Last Ex-Dividend
Sep 4, 2025
The reported statements, read against the company's own industry.
Financials view
Market Capitalization
64.82BINR677.36M · vs all stocks (USD)
Trailing P/E
32.65xvs Biotechnology peers
Revenue (TTM)
8.73BINR91.17M · vs all stocks (USD)
Profit Margin
22.74%vs Biotechnology peers
Beta
0.6670xvs all stocks
52-Week Change
21.62%vs all stocks
Market Capitalization
64.82BINR677.36M · vs all stocks (USD)
Enterprise Value
64.54BINR674.33M · vs all stocks (USD)
Trailing P/E
32.65xvs Biotechnology peers
Forward P/E
20.75xvs Biotechnology peers
Price to Sales (TTM)
7.43xvs Biotechnology peers
Price to Book (MRQ)
5.41xvs Biotechnology peers
Enterprise to Revenue
7.40xvs Biotechnology peers
Enterprise to EBITDA
22.29xvs Biotechnology peers
Gross Margin
61.91%vs Biotechnology peers
Profit Margin
22.74%vs Biotechnology peers
Operating Margin
21.40%vs Biotechnology peers
Return on Assets (TTM)
15.41%vs Biotechnology peers
Return on Equity (TTM)
17.46%vs Biotechnology peers
Revenue (TTM)
8.73BINR91.17M · vs all stocks (USD)
Revenue per Share (TTM)
108.44INRUpdated Aug 22, 2026Quarterly Revenue Growth
32.60%vs Biotechnology peers
Gross Profit (TTM)
5.94BINR62.05M · vs all stocks (USD)
EBITDA (TTM)
3.06BINR31.93M · vs all stocks (USD)
Net Income (TTM)
1.98BINR20.73M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
-30.90%vs Biotechnology peers
Operating Cash Flow (TTM)
1.86BINR19.41M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
2.09BINR21.85M · vs all stocks (USD)
Trailing Annual Dividend Rate
1.00INRUpdated Aug 22, 2026Trailing Annual Dividend Yield
0.12%vs all stocks
Payout Ratio
4.06%vs Biotechnology peers
Revenue
8.28BINRFY2026 · Mar 31, 2026Cost of Goods Sold
2.54BINRFY2026 · Mar 31, 2026Gross Profit
5.74BINRFY2026 · Mar 31, 2026Operating Income
2.66BINR27.76M · vs all stocks (USD)
Pre-tax Income
2.75BINRFY2026 · Mar 31, 2026Income Tax Expense
656.59MINRFY2026 · Mar 31, 2026Net Income
2.09BINRFY2026 · Mar 31, 2026EBIT
2.77BINRFY2026 · Mar 31, 2026EBITDA (Income Statement)
3.06BINRFY2026 · Mar 31, 2026Other Operating Expenses
1.83BINRFY2026 · Mar 31, 2026Non-operating Interest Expense
18.89MINRFY2026 · Mar 31, 2026EPS (Basic)
25.98INRFY2026 · Mar 31, 2026EPS (Diluted)
25.98INRFY2026 · Mar 31, 2026Basic Shares Outstanding
80.49MSharesFY2026 · Mar 31, 2026Diluted Shares Outstanding
80.49MSharesFY2026 · Mar 31, 2026Preferred Stock Dividends
0.00INRFY2026 · Mar 31, 2026Operating Cash Flow
1.82BINRFY2026 · Mar 31, 2026Free Cash Flow
292.90MINRFY2026 · Mar 31, 2026Cash & Cash Equivalents (End of Period)
788.67MINRFY2026 · Mar 31, 2026Starting Profit (CF Statement)
2.75BINRFY2026 · Mar 31, 2026Other Non-cash Items
-94.54MINRFY2026 · Mar 31, 2026Change in Accounts Receivable (CF)
-847.27MINRFY2026 · Mar 31, 2026Change in Other Assets/Liabilities
9.27MINRFY2026 · Mar 31, 2026Capital Expenditures
-1.52BINRFY2026 · Mar 31, 2026Net Investing Cash Flow
-1.52BINRFY2026 · Mar 31, 2026Net Short-term Debt Issuance
0.00INRFY2026 · Mar 31, 2026Common Dividends Paid
-80.48MINRFY2026 · Mar 31, 2026Net Financing Cash Flow
-80.48MINRFY2026 · Mar 31, 2026Shares Outstanding
80.48MSharesUpdated Aug 22, 2026Float Shares
25.49MSharesUpdated Aug 22, 2026% Held by Insiders
71.28%vs all stocks
% Held by Institutions
4.82%vs all stocks
Total Cash (MRQ)
788.67MINR8.24M · vs all stocks (USD)
Total Cash per Share (MRQ)
9.81INRUpdated Aug 22, 2026Total Debt (MRQ)
54.35MINR567.90K · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.0045xvs Biotechnology peers
Current Ratio (MRQ)
4.40xvs Biotechnology peers
Book Value per Share (MRQ)
148.77INRUpdated Aug 22, 2026Total Assets
13.57BINR141.80M · vs all stocks (USD)
Total Current Assets
5.32BINRFY2026 · Mar 31, 2026Total Liabilities
1.59BINRFY2026 · Mar 31, 2026Total Non-current Assets
8.25BINRFY2026 · Mar 31, 2026Total Non-current Liabilities
383.30MINRFY2026 · Mar 31, 2026Total Current Liabilities
1.21BINRFY2026 · Mar 31, 2026Cash & Cash Equivalents
375.46MINRFY2026 · Mar 31, 2026Other Short-term Investments
413.21MINRFY2026 · Mar 31, 2026Accounts Receivable
2.19BINRFY2026 · Mar 31, 2026Inventory
1.60BINRFY2026 · Mar 31, 2026Accounts Payable
1.11BINRFY2026 · Mar 31, 2026Short-term Debt
2.46MINRFY2026 · Mar 31, 2026Other Current Liabilities
62.40MINRFY2026 · Mar 31, 2026Long-term Debt
51.89MINRFY2026 · Mar 31, 2026Common Stock (Book)
160.97MINRFY2026 · Mar 31, 2026Total Shareholders' Equity
11.98BINR125.15M · vs all stocks (USD)
52-Week Low
545.50INRUpdated Aug 22, 202652-Week High
1.08KINRUpdated Aug 22, 202652-Week Change
21.62%vs all stocks
Beta
0.6670xvs all stocks
50-Day MA
887.31INRUpdated Aug 22, 2026200-Day MA
751.98INRUpdated Aug 22, 2026Avg 10-Day Volume
496.19KSharesUpdated Aug 22, 2026Avg 30-Day Volume
299.14KSharesUpdated Aug 22, 2026Diluted EPS (TTM)
24.66INRUpdated Aug 22, 20267 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
MRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total Liabilities
Cash covers most of its debt, with earnings high against its liabilities.
Reads
How does this company use capital?
Three Asset-Base Ratios Elevated
It gets more sales from its assets than its industry does, and a lot of profit from them too.
Reads
Cash-Flow Ratios Elevated
More of its sales turn into cash than in its industry, and less of that cash is consumed by reinvestment than at most of its peers.
Reads
Industry-Benchmarked Return on Capital Elevated
It earns more on its assets and its equity than its industry, and gets more sales from those assets.
Reads
Revenue Growing With Receivables Growing
Revenue has risen three years, and what customers owe has risen with it.
Reads
ROE, ROA, And Operating ROA Elevated
It earns more on its equity than its industry does, and on its assets too — not on borrowing alone.
Reads
Is this company growing?
Multi-Year Revenue, Profit, And Income Growth
Revenue has risen in each of three years, gross profit in each of four, and it has made a profit in all five.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Return on assets is 15.4%, higher than 95% of its Biotechnology peers (median -20.1%)Significant
Return on assets: 0.15Industry median: -0.20Industry P95: 0.15Peers compared: 261
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Levered free cash flow is $21.85M, above the global median of $16.24MNotable
Levered free cash flow (USD): 21,850,948.8Global Median: 16,239,329.704
Companies that share the same coordination system — how they create, deliver, or capture value.
Qianjiang Yongan Pharmaceutical Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Shanghai ShenQi Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Gyre Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Xiangxue Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Henan Taloph Pharmaceutical Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Hunan Fangsheng Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Newland Pharmaceuticals Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Tianjin Lisheng Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
BridgeBio Oncology Therapeutics, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Zhejiang Yatai Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Companies that share active interpretations — structural patterns currently present in both stocks.
Catalyst Pharmaceuticals Inc.
7 interpretationsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesROE, ROA, And Operating ROA ElevatedCash-Flow Ratios ElevatedRevenue Growing With Receivables GrowingMulti-Year Revenue, Profit, And Income GrowthIndustry-Benchmarked Return on Capital ElevatedThree Asset-Base Ratios Elevated
NVIDIA Corporation
7 interpretationsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesROE, ROA, And Operating ROA ElevatedCash-Flow Ratios ElevatedRevenue Growing With Receivables GrowingMulti-Year Revenue, Profit, And Income GrowthIndustry-Benchmarked Return on Capital ElevatedThree Asset-Base Ratios Elevated
Harmony Biosciences Holdings, Inc.
7 interpretationsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesROE, ROA, And Operating ROA ElevatedCash-Flow Ratios ElevatedRevenue Growing With Receivables GrowingMulti-Year Revenue, Profit, And Income GrowthIndustry-Benchmarked Return on Capital ElevatedThree Asset-Base Ratios Elevated